Literature DB >> 25736504

Affinity binding of antibodies to supermacroporous cryogel adsorbents with immobilized protein A for removal of anthrax toxin protective antigen.

Ganesh C Ingavle1, Les W J Baillie2, Yishan Zheng3, Elzbieta K Lis4, Irina N Savina5, Carol A Howell6, Sergey V Mikhalovsky7, Susan R Sandeman8.   

Abstract

Polymeric cryogels are efficient carriers for the immobilization of biomolecules because of their unique macroporous structure, permeability, mechanical stability and different surface chemical functionalities. The aim of the study was to demonstrate the potential use of macroporous monolithic cryogels for biotoxin removal using anthrax toxin protective antigen (PA), the central cell-binding component of the anthrax exotoxins, and covalent immobilization of monoclonal antibodies. The affinity ligand (protein A) was chemically coupled to the reactive hydroxyl and epoxy-derivatized monolithic cryogels and the binding efficiencies of protein A, monoclonal antibodies to the cryogel column were determined. Our results show differences in the binding capacity of protein A as well as monoclonal antibodies to the cryogel adsorbents caused by ligand concentrations, physical properties and morphology of surface matrices. The cytotoxicity potential of the cryogels was determined by an in vitro viability assay using V79 lung fibroblast as a model cell and the results reveal that the cryogels are non-cytotoxic. Finally, the adsorptive capacities of PA from phosphate buffered saline (PBS) were evaluated towards a non-glycosylated, plant-derived human monoclonal antibody (PANG) and a glycosylated human monoclonal antibody (Valortim(®)), both of which were covalently attached via protein A immobilization. Optimal binding capacities of 108 and 117 mg/g of antibody to the adsorbent were observed for PANG attached poly(acrylamide-allyl glycidyl ether) [poly(AAm-AGE)] and Valortim(®) attached poly(AAm-AGE) cryogels, respectively, This indicated that glycosylation status of Valortim(®) antibody could significantly increase (8%) its binding capacity relative to the PANG antibody on poly(AAm-AGE)-protien-A column (p < 0.05). The amounts of PA which remained in the solution after passing PA spiked PBS through PANG or Valortim bound poly(AAm-AGE) cryogel were significantly (p < 0.05) decreased relative to the amount of PA remained in the solution after passing through unmodified as well as protein A modified poly(AAm-AGE) cryogel columns, indicates efficient PA removal from spiked PBS over 60 min of circulation. The high adsorption capacity towards anthrax toxin PA of the cryogel adsorbents indicated potential application of these materials for treatment of Bacillus anthracis infection.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Anthrax toxin protective antigen (PA); Anthrax toxin specific monoclonal antibodies; Protein A affinity cryogels; Supermacroporous cryogel

Mesh:

Substances:

Year:  2015        PMID: 25736504     DOI: 10.1016/j.biomaterials.2015.01.039

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  3 in total

1.  Composite Cryogel with Polyelectrolyte Complexes for Growth Factor Delivery.

Authors:  Bolat Sultankulov; Dmitriy Berillo; Sholpan Kauanova; Sergey Mikhalovsky; Lyuba Mikhalovska; Arman Saparov
Journal:  Pharmaceutics       Date:  2019-12-04       Impact factor: 6.321

2.  A simple method for the production of large volume 3D macroporous hydrogels for advanced biotechnological, medical and environmental applications.

Authors:  Irina N Savina; Ganesh C Ingavle; Andrew B Cundy; Sergey V Mikhalovsky
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

3.  Bioinspired detoxification of blood: The efficient removal of anthrax toxin protective antigen using an extracorporeal macroporous adsorbent device.

Authors:  Ganesh Ingavle; Les Baillie; Nathan Davies; Nigel Beaton; Yishan Zheng; Sergey Mikhalovsky; Susan Sandeman
Journal:  Sci Rep       Date:  2018-05-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.